<p>Ginkgo Bioworks（纽约证券交易所代码：DNA - 获取免费报告）预计将在 2025 年 8 月 7 日星期四市场收盘后发布其 2025 年第二季度财报。分析师预计 Ginkgo Bioworks 每股收益为（$1.44），季度收入为 4160 万美元。Ginkgo Bioworks 已将其 2025 财年的指引设定为每股收益。</p>
<p>Ginkgo Bioworks（纽约证券交易所代码：DNA - 获取免费报告）最近一次发布季度财报是在 5 月 6 日星期二。该公司报告的季度每股收益为（$1.58），低于市场共识预期的（$1.23），差距为（$0.35）。Ginkgo Bioworks 的股本回报率为负的 52.35%，净利润率为负的 198.84%。该公司在本季度的收入为 4832 万美元，而分析师的预期为 3870 万美元。分析师平均预计 Ginkgo Bioworks 在当前财年的每股收益为-$10，下一财年的每股收益为-$6。</p>
<p>获取 <strong>Ginkgo Bioworks</strong> 的提醒：</p>
<h2>Ginkgo Bioworks 股票表现</h2>
<p>DNA 股票在星期五开盘价为$12.18。该公司的 50 日移动平均价格为$10.05，200 日移动平均价格为$9.35。Ginkgo Bioworks 的 52 周最低价为$5.00，52 周最高价为$16.85。该公司的市值为 7.129 亿美元，市盈率为-1.33，贝塔值为 1.50。</p>
<h2>机构投资者对 Ginkgo Bioworks 的看法</h2>
<p>一些对冲基金最近调整了对该公司的持股。Acadian Asset Management LLC 在第一季度购买了 Ginkgo Bioworks 的新头寸，价值$120,000。高盛集团在第一季度将其在 Ginkgo Bioworks 的持股增加了 25.4%。高盛集团目前拥有 686,767 股该公司的股票，价值$3,915,000，此前在上个季度又购买了 139,126 股。Millennium Management LLC 在第一季度将其在 Ginkgo Bioworks 的持股增加了 113.1%。Millennium Management LLC 目前拥有 1,427,600 股该公司的股票，价值$8,137,000，此前在上个季度又购买了 757,535 股。最后，AQR Capital Management LLC 在第一季度将其在 Ginkgo Bioworks 的持股增加了 322.6%。AQR Capital Management LLC 目前拥有 158,939 股该公司的股票，价值$906,000，此前在上个季度又购买了 121,326 股。机构投资者持有该公司 78.63% 的股票。</p>
<h2>Ginkgo Bioworks 公司简介</h2>
<p>（获取免费报告）</p>
<p>Ginkgo Bioworks Holdings, Inc 及其子公司在美国开发细胞编程平台。该平台用于编程细胞，以实现生物产品的生产，如新型治疗药物、食品成分和石油衍生化学品。它服务于制药和生物技术、农业、工业和环境、食品和营养、消费和技术以及政府和国防等行业。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Ginkgo Bioworks</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>PG&amp;E 是人工智能的投资机会吗？为什么期权交易者在大举下注</li>
<li>什么是股息收割策略，投资者如何从中获利？</li>
<li>MarketBeat 周回顾 – 07/28 - 08/01</li>
<li>如何选择顶级股票</li>
<li>Hims &amp; Hers 会跟随诺和诺德下跌吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUROQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUROQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Ginkgo Bioworks 吗？</h2>
<p>在考虑 Ginkgo Bioworks 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Ginkgo Bioworks 并不在名单上。</p>
<p>虽然 Ginkgo Bioworks 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Ginkgo Bioworks（纽约证券交易所代码：DNA）将于 8 月 7 日发布 2025 年第二季度财报，分析师预测每股亏损 1.44 美元，收入为 4160 万美元。该公司此前报告了 2025 年第一季度每股亏损 1.58 美元，未能达到预期。Ginkgo Bioworks 的市值为 7.129 亿美元，股本回报率为负 52.35%。机构投资者持有该股票的 78.63%，近期有高盛和千禧年管理等公司进行了大量购买</p>

<p>Ginkgo Bioworks (NYSE:DNA - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Ginkgo Bioworks to post earnings of ($1.44) per share and revenue of $41.60 million for the quarter. Ginkgo Bioworks has set its FY 2025 guidance at EPS.</p>
<div class="lb-trans"><p>Ginkgo Bioworks（纽约证券交易所代码：DNA - 获取免费报告）预计将在 2025 年 8 月 7 日星期四市场收盘后发布其 2025 年第二季度财报。分析师预计 Ginkgo Bioworks 每股收益为（$1.44），季度收入为 4160 万美元。Ginkgo Bioworks 已将其 2025 财年的指引设定为每股收益。</p>
</div><p>Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. The company had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. On average, analysts expect Ginkgo Bioworks to post $-10 EPS for the current fiscal year and $-6 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Ginkgo Bioworks（纽约证券交易所代码：DNA - 获取免费报告）最近一次发布季度财报是在 5 月 6 日星期二。该公司报告的季度每股收益为（$1.58），低于市场共识预期的（$1.23），差距为（$0.35）。Ginkgo Bioworks 的股本回报率为负的 52.35%，净利润率为负的 198.84%。该公司在本季度的收入为 4832 万美元，而分析师的预期为 3870 万美元。分析师平均预计 Ginkgo Bioworks 在当前财年的每股收益为-$10，下一财年的每股收益为-$6。</p>
</div><p>Get <strong>Ginkgo Bioworks</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ginkgo Bioworks</strong> 的提醒：</p>
</div><h2>Ginkgo Bioworks Stock Performance</h2>
<div class="lb-trans"><h2>Ginkgo Bioworks 股票表现</h2>
</div><p>DNA stock opened at $12.18 on Friday. The firm has a 50 day moving average price of $10.05 and a 200-day moving average price of $9.35. Ginkgo Bioworks has a 52-week low of $5.00 and a 52-week high of $16.85. The firm has a market capitalization of $712.90 million, a price-to-earnings ratio of -1.33 and a beta of 1.50.</p>
<div class="lb-trans"><p>DNA 股票在星期五开盘价为$12.18。该公司的 50 日移动平均价格为$10.05，200 日移动平均价格为$9.35。Ginkgo Bioworks 的 52 周最低价为$5.00，52 周最高价为$16.85。该公司的市值为 7.129 亿美元，市盈率为-1.33，贝塔值为 1.50。</p>
</div><h2>Institutional Investors Weigh In On Ginkgo Bioworks</h2>
<div class="lb-trans"><h2>机构投资者对 Ginkgo Bioworks 的看法</h2>
</div><p>A number of hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC bought a new position in Ginkgo Bioworks in the 1st quarter worth $120,000. Goldman Sachs Group Inc. lifted its stake in Ginkgo Bioworks by 25.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 686,767 shares of the company's stock worth $3,915,000 after purchasing an additional 139,126 shares in the last quarter. Millennium Management LLC lifted its stake in Ginkgo Bioworks by 113.1% in the 1st quarter. Millennium Management LLC now owns 1,427,600 shares of the company's stock worth $8,137,000 after purchasing an additional 757,535 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in Ginkgo Bioworks by 322.6% in the 1st quarter. AQR Capital Management LLC now owns 158,939 shares of the company's stock worth $906,000 after purchasing an additional 121,326 shares in the last quarter. Institutional investors own 78.63% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近调整了对该公司的持股。Acadian Asset Management LLC 在第一季度购买了 Ginkgo Bioworks 的新头寸，价值$120,000。高盛集团在第一季度将其在 Ginkgo Bioworks 的持股增加了 25.4%。高盛集团目前拥有 686,767 股该公司的股票，价值$3,915,000，此前在上个季度又购买了 139,126 股。Millennium Management LLC 在第一季度将其在 Ginkgo Bioworks 的持股增加了 113.1%。Millennium Management LLC 目前拥有 1,427,600 股该公司的股票，价值$8,137,000，此前在上个季度又购买了 757,535 股。最后，AQR Capital Management LLC 在第一季度将其在 Ginkgo Bioworks 的持股增加了 322.6%。AQR Capital Management LLC 目前拥有 158,939 股该公司的股票，价值$906,000，此前在上个季度又购买了 121,326 股。机构投资者持有该公司 78.63% 的股票。</p>
</div><h2>Ginkgo Bioworks Company Profile</h2>
<div class="lb-trans"><h2>Ginkgo Bioworks 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.</p>
<div class="lb-trans"><p>Ginkgo Bioworks Holdings, Inc 及其子公司在美国开发细胞编程平台。该平台用于编程细胞，以实现生物产品的生产，如新型治疗药物、食品成分和石油衍生化学品。它服务于制药和生物技术、农业、工业和环境、食品和营养、消费和技术以及政府和国防等行业。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Ginkgo Bioworks</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>Is PG&amp;E an AI Power Play? Why Options Traders Are Betting Big</li>
<li>What is a Dividend Harvesting Strategy and How Can Investors Profit from it?</li>
<li>MarketBeat Week in Review – 07/28 - 08/01</li>
<li>How to Choose Top Rated Stocks</li>
<li>Will Hims &amp; Hers Fall Along With Novo Nordisk?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Ginkgo Bioworks</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>PG&amp;E 是人工智能的投资机会吗？为什么期权交易者在大举下注</li>
<li>什么是股息收割策略，投资者如何从中获利？</li>
<li>MarketBeat 周回顾 – 07/28 - 08/01</li>
<li>如何选择顶级股票</li>
<li>Hims &amp; Hers 会跟随诺和诺德下跌吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUROQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NYSE&amp;Symbol=DNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ginkgo Bioworks Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Ginkgo Bioworks 吗？</h2>
</div><p>Before you consider Ginkgo Bioworks, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ginkgo Bioworks 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Ginkgo Bioworks 并不在名单上。</p>
</div><p>While Ginkgo Bioworks currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ginkgo Bioworks 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ginkgo Bioworks (DNA) 预计将在周四发布财报